

R E M A R K S

Regarding Item No. 4 at the top of page 3 of the Office Action, applicants have informed the undersigned that JP 5-503281 is a Japanese translation of WO 91/10448.

Applicants are pleased to note that claims 4, 18 and 46 were deemed to be allowable over the prior art (see Item No. 19 in the last sentence on page 9 of the Office Action). In the previously presented claims 4, 18 and 46, the anti-human Fas antibody is monoclonal antibody HFE7A or a humanized antibody thereof.

The claims have been amended to delete the anti-human Fas antibody CH11. All the present claims are therefore directed to the anti-human Fas antibody being monoclonal antibody HFE7A or a humanized antibody thereof.

The features deleted from claim 4 form the basis of new claim 49.

The features deleted from claim 18 form the basis of new claim 50.

New claim 51 recites the feature recited in claims 44 and 46 to 48.

Claims 1 to 3 were rejected under 35 USC 103 as being unpatentable over McGahon et al., British Journal of Haematology, 101, 539-547 (1998) in view of Ramer et al. USP 6,001,962 for the reasons set forth in Item No. 17 on page 8 of the Office Action.

Claims 1, 3, 13, 14, 17, 27, 28, 44, 45, 47 and 48 were rejected under 35 USC 103 as being unpatentable over McGahon et al. and Ramer et al. in view of Genestier et al., J. Clin. Invest., 102(2), 322-328 (1998) and Fujisawa et al., J. Clin. Invest., 98(2), 271-278 (1998) for the reasons set forth in Item No. 18 beginning at the bottom of page 8 and continuing to the bottom of page 9 fo the Office Action.

Both of the prior art rejections are directed to the CH11 antibody.


As discussed above, the present claims are directed to the utilization of monoclonal antibody HFE7A or a humanized antibody of HFE7A, which are IgG type antibodies. McGahon et al. teach in the last paragraph of page 542 that anti-Fas IgG has no synergistic or additive effect with chemotherapeutic drugs and thus teach away from the presently claimed invention.

It is therefore respectfully requested that the 35 USC 103 rejections be withdrawn.

Reconsideration is requested. Allowance is solicited.

If the Examiner has any comments, questions, objections or recommendations, the Examiner is invited to telephone the undersigned at the telephone number given below for prompt action.

Respectfully submitted,



RICHARD S. BARTH
REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN & CHICK, P.C.
767 THIRD AVENUE - 25TH FLOOR
NEW YORK, NEW YORK 10017-2023
Tel. Nos. (212) 319-4900
(212) 319-4551/Ext. 219
Fax No. (212) 319-5101
E-Mail Address: BARTH@FHGC-LAW.COM
RSB/ddf